Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix
NETkids
The Value of Complementary Right-sided Hemicolectomy for Pediatric Patients With High-risk Neuroendocrine Tumors (NETs) of the Appendix; Towards the Development of an (Inter-) National Consensus Guideline for the Pediatric Population.
1 other identifier
observational
1,000
1 country
1
Brief Summary
The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children. .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2023
CompletedFirst Submitted
Initial submission to the registry
May 8, 2023
CompletedFirst Posted
Study publicly available on registry
June 26, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedJuly 30, 2024
July 1, 2024
1.7 years
May 8, 2023
July 29, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Disease free survival rate
defined as alive and free of recurrence of NET at telephone follow-up performed for this study purpose
cross-sectional design. follow-up will be done in 2023/2024
Recurrence rate
defined as histopathologically proven metastasis/residual tumor at appendiceal stump of NET after a disease free period
cross-sectional design. follow-up will be done in 2023/2024
Secondary Outcomes (9)
Overall survival rate
cross-sectional design. follow-up will be done in 2023/2024
Complications directly related to primary and secondary treatment divided into major and minor complications according to Clavien-dindo.
cross-sectional design. follow-up will be done in 2023/2024
Number of hospital readmission for complications related to treatment of NET
cross-sectional design. follow-up will be done in 2023/2024
Length of hospital stay
cross-sectional design. follow-up will be done in 2023/2024
number of imaging studies performed for follow-up of NET
cross-sectional design. follow-up will be done in 2023/2024
- +4 more secondary outcomes
Eligibility Criteria
All patients treated for an appendiceal neuro endocrine tumour before the age of 18 during 1990 and 2020
You may qualify if:
- All patients that were treated for an appendiceal NET before the age of 18 years old
- Time period: 1990-2020
You may not qualify if:
- Other appendiceal malignancies/tumours, for example:
- goblet cell carcinoma
- adenocarcinoma
- neuroendocrine carcinoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Amsterdam UMC
Amsterdam-Zuidoost, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Ramon R Gorter, MD PhD
Amsterdam UMC, department of pediatric surgery
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
May 8, 2023
First Posted
June 26, 2023
Study Start
May 1, 2023
Primary Completion
December 31, 2024
Study Completion
June 1, 2025
Last Updated
July 30, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share
individual participant data will not be shared with other researchers. Collaborating institution will however enter participant data in a coded/pseudonimyzed manner in Castor EDC database.